InvestorsHub Logo
Followers 21
Posts 1385
Boards Moderated 0
Alias Born 06/14/2017

Re: peachy90 post# 44676

Tuesday, 08/06/2019 2:34:31 PM

Tuesday, August 06, 2019 2:34:31 PM

Post# of 233278
Primary endpoint in Phase III trial for combination HIV therapy in heavily treatment experienced patients, p value of .0032. If it's been a while since you had statistics, that means there is a 32 out of 10,000 chance that the results in the trial occurred by chance.

Great question, and thanks for the opportunity to point out the unquestioned efficacy of leronlimab in HIV combination therapy.

I can also answer your safety and SAE questions, so feel free to ask those next.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent CYDY News